Caris Life Sciences aims to standardize MET immunohistochemistry testing for non-squamous non-small cell lung cancer to enhance molecular insights and treatment personalization. MET protein expression ...
Study Finds on MSN
Blood test accurately detects 81% of earliest lung cancers by looking for molecular chaos
In A Nutshell Johns Hopkins researchers developed a blood test that catches 81% of stage IA lung cancers (the earliest, most ...
Evaluating lung cancer clinical characteristics and tumor subtypes using cell-free DNA fragmentomes. A retrospective study of induction immunochemotherapy followed by definitive chemoradiotherapy and ...
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung cancers are non-small cell lung cancers, in which tumor cells are larger and ...
Examination of post-radiation survey data from the navigator-assisted hypofractionation (NAVAH) phase I trial in African-American prostate cancer patients. Multivariable logistic regression analysis ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces ...
Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results